Jimmy Ou
YOU?
Author Swipe
View article: Data from Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia
Data from Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia Open
Thrombocytopenia is a common adverse event in cancer patients treated with antibody–drug conjugates (ADC), including AGS-16C3F, an ADC targeting ENPP3 (ectonucleotide pyrophosphatase/phosphodiesterase-3) and trastuzumab emtansine (T-DM1). …
View article: Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer Open
Here, we report the development of an antibody–drug conjugate, ASG-5ME, which targets the solute carrier receptor SLC44A4. SLC44A4 is a member of a family of putative choline transporters that we show to be markedly upregulated in a variet…
View article: Supplementary methods, legends, Figures S1-S5, and Tables S1-S2 from Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia
Supplementary methods, legends, Figures S1-S5, and Tables S1-S2 from Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia Open
Fig. S1. Structure of AGS-16C3F; Figure S2. ENPP3 was not expressed in megakaryocytes; Figure S3. AGS-16C3F did not affect platelet activation; Figure S4. Maturing MKs did not express ENPP3; Figure S5. Fc blocker inhibited FcγRIIA pathway …
View article: Supplementary methods, legends, Figures S1-S5, and Tables S1-S2 from Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia
Supplementary methods, legends, Figures S1-S5, and Tables S1-S2 from Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia Open
Fig. S1. Structure of AGS-16C3F; Figure S2. ENPP3 was not expressed in megakaryocytes; Figure S3. AGS-16C3F did not affect platelet activation; Figure S4. Maturing MKs did not express ENPP3; Figure S5. Fc blocker inhibited FcγRIIA pathway …
View article: Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer Open
Here, we report the development of an antibody–drug conjugate, ASG-5ME, which targets the solute carrier receptor SLC44A4. SLC44A4 is a member of a family of putative choline transporters that we show to be markedly upregulated in a variet…
View article: Data from Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia
Data from Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia Open
Thrombocytopenia is a common adverse event in cancer patients treated with antibody–drug conjugates (ADC), including AGS-16C3F, an ADC targeting ENPP3 (ectonucleotide pyrophosphatase/phosphodiesterase-3) and trastuzumab emtansine (T-DM1). …
View article: Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer Open
Figure S1. Proteolytic release of MMAE from ASG-5ME; Figure S2. SLC44A4 RNA expression in normal and tumor specimens from combined Oncomine data sets; Figure S3: Expression of SLC44A4 in OVCAR-5 cells determined by FACS.
View article: Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer Open
Figure S1. Proteolytic release of MMAE from ASG-5ME; Figure S2. SLC44A4 RNA expression in normal and tumor specimens from combined Oncomine data sets; Figure S3: Expression of SLC44A4 in OVCAR-5 cells determined by FACS.
View article: Supplemental Figure 4 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 4 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 4. Pharmacokinetics of AGS16F. Mice were injected with a single dose of AGS16F.
View article: Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 2. AGS16-7.8 does not inhibit the enzymatic activity of purified ENPP3.
View article: Supplemental Table 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Table 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Table 2. Comparability of Anti-ENPP3 ADC Produced in Hybridoma or CHO Cells
View article: Supplemental Figure 4 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 4 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 4. Pharmacokinetics of AGS16F. Mice were injected with a single dose of AGS16F.
View article: Supplemental Figure 4 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 4 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 4. Pharmacokinetics of AGS16F. Mice were injected with a single dose of AGS16F.
View article: Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 2. AGS16-7.8 does not inhibit the enzymatic activity of purified ENPP3.
View article: Supplemental Figure 5 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 5 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 5. Immunostaining for cleaved PARP-1 and PPH3 in tumors.
View article: Supplemental Figure 3A and 3B from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 3A and 3B from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 3A. Mapping of AGS16-7.8 binding to different ENNP3 domains. Supplemental Figure 3B. Western blots for mapping recognition of epitopes in ENPP3 ECD fragments.
View article: Supplemental Methods from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Methods from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Methods
View article: Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 2. AGS16-7.8 does not inhibit the enzymatic activity of purified ENPP3.
View article: Supplemental Table 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Table 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Table 1. Quantification of ENPP3 Expression in Various Carcinomas
View article: Supplemental Table 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Table 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Table 2. Comparability of Anti-ENPP3 ADC Produced in Hybridoma or CHO Cells
View article: Supplemental Figure 3A and 3B from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 3A and 3B from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 3A. Mapping of AGS16-7.8 binding to different ENNP3 domains. Supplemental Figure 3B. Western blots for mapping recognition of epitopes in ENPP3 ECD fragments.
View article: Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 2. AGS16-7.8 does not inhibit the enzymatic activity of purified ENPP3.
View article: Supplemental Table 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Table 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Table 1. Quantification of ENPP3 Expression in Various Carcinomas
View article: Supplemental Figure 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 1. AGS16-7.8 and AGS16F do not bind to ENPP1 or ENPP2 proteins.
View article: Supplemental Table 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Table 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Table 2. Comparability of Anti-ENPP3 ADC Produced in Hybridoma or CHO Cells
View article: Supplemental Table 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Table 2 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Table 2. Comparability of Anti-ENPP3 ADC Produced in Hybridoma or CHO Cells
View article: Supplemental Figure 5 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 5 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 5. Immunostaining for cleaved PARP-1 and PPH3 in tumors.
View article: Supplemental Methods from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Methods from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Methods
View article: Supplemental Figure 5 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 5 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 5. Immunostaining for cleaved PARP-1 and PPH3 in tumors.
View article: Supplemental Figure 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Supplemental Figure 1 from AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma Open
Supplemental Figure 1. AGS16-7.8 and AGS16F do not bind to ENPP1 or ENPP2 proteins.